- Baudax Bio Inc (NASDAQ:BXRX) announced the outcome of its first interim analysis in a Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
- The trial evaluates three doses of BX1000 to a standard dose of rocuronium and expects to enroll 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
- Additionally, the trial evaluates the safety and tolerability profile of BX1000 and rocuronium in this patient population.
- The pre-planned interim analysis evaluated the intubating conditions for each patient after administering the study drug in a blinded fashion.
- All 20 patients were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds. Nineteen of the subjects were successfully intubated following the assessment at 60 seconds, and the remaining subject followed the assessment at 90 seconds.
- Study treatments were generally well tolerated, with no severe or serious adverse events.
- The company plans to complete enrollment in the study in Q1 and share the topline results for the study in April 2023.
- Price Action: BXRX shares are up 39.40% at $4.39 on the last check Tuesday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.